Differential expression of perlecan receptors, α-dystroglycan and integrin β1, before and after invasion of oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 40, Issue 7, 2011, Pages 552-559

  Ahsan, Md Shahidul ^a   Yamazaki, Manabu ^a   Maruyama, Satoshi ^b   Kobayashi, Takanori ^b   Ida Yonemochi, Hiroko ^b   Hasegawa, Mayumi ^a   Henry Ademola, Adeola ^a   Cheng, Jun ^a   Saku, Takashi ^a,b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

dystroglycan; Carcinoma in situ; Integrin 1; Oral mucosa; Perlecan; Squamous cell carcinoma

Indexed keywords

ALPHA DYSTROGLYCAN; BETA1 INTEGRIN; KI 67 ANTIGEN; MESSENGER RNA; PERLECAN;

ARTICLE; BASAL CELL; CANCER CELL; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM; EPITHELIUM DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERCELLULAR SPACE; MAJOR CLINICAL STUDY; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STROMA;

ANTIGENS, CD29; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE; DYSTROGLYCANS; EPITHELIAL CELLS; EPITHELIUM; EXTRACELLULAR SPACE; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; RNA, MESSENGER; STROMAL CELLS;

EID: 79960639059     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00990.x     Document Type: Article

References (43)

1. Pindborg JJ, Reichart PA, Smith CJ, van derWaalI. Histological typing of cancer and precancer of the oral mucosa. World Health Organization International Histological Classification of Tumours. Berlin: Springer-Verlag, 1997; 24-6.
2. Ikarashi T, Ida-Yonemochi H, Ohshiro K, Cheng J, Saku T. Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 2004; 33: 87-95.
3. Kobayashi T, Maruyama S, Cheng J, et al. Histopathological varieties of oral carcinoma in situ: diagnosis aided by immunohistochemistry dealing with the second basal cell layer as the proliferating center of oral mucosal epithelia. Pathol Int 2010; 60: 156-66.
4. Ida-Yonemochi H, Saku T. Perlecan, a heparan sulfate proteoglycan, is a major constituent of the intraepithelial stroma functioning in tooth morphogenesis. J Oral Biosci 2006; 48: 233-43.
5. Ida-Yonemochi H, Ohshiro K, Swelam W, Metwaly H, Saku T. Perlecan, a basement membrane-type heparin sulfate proteoglycan, in the enamel organ: its intraepithelial localization in the stellate reticulum. J Histochem Cytochem 2005; 53: 763-72.
6. Ohtani H, Nakamura S, Watanabe Y, Mizoi T, Saku T, Nagura H. Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract. Lab Invest 1993; 68: 520-7.
7. Ida-Yonemochi H, Ikarashi T, Nagata M, Hoshina H, Takagi R, Saku T. The basement membrane-type heparin sulfate proteoglycan (perlecan) in ameloblastomas: its intercellular localization in stellate reticulum-like foci and biosynthesis by tumor cells in culture. Virchows Arch 2002; 441: 165-73.
8. Saku T, Cheng J, Okabe H, Koyama Z. Immunolocalization of basement membrane molecules in the stroma of salivary gland pleomorphic adenoma. J Oral Pathol Med 1990; 19: 208-14.
9. Cheng J, Saku T, Okabe H, Furthmayr H. Basement membranes in adenoid cystic carcinoma. An immunohistochemical study. Cancer 1992; 69: 2631-40.
10. Tsuneki M, Cheng J, Maruyama S, Ida-Yonemochi H, Nakajima M, Saku T. Perlecan-rich epithelial linings as a background of proliferative potentials of keratocystic odontogenic tumor. J Oral Pathol Med 2008; 37: 287-93.
11. Knox SM, Whitelock JM. Perlecan: how does one molecule do so many things? Cell Mol Life Sci 2006; 63: 2435-45.
12. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 2005; 6: 646-56.
13. Maruyama S, Cheng J, Shingaki S, et al. Establishment and characterization of pleomorphic adenoma cell systems: an in-vitro demonstration of carcinomas arising secondarily from adenomas in the salivary gland. BMC Cancer 2009; 9: 247.
14. Maruyama S, Cheng J, Yamazaki M, Liu A, Saku T. Keratinocyte growth factor colocalized with perlecan at the site of capsular invasion and vascular involvement in salivary pleomorphic adenomas. J Oral Pathol Med 2009; 38: 377-85.
15. Swelam W, Ida-Yonemochi H, Maruyama S, Ohshiro K, Cheng J, Saku T. Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma. Virchows Arch 2005; 446: 653-62.
16. Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J 2003; 22: 2318-23.
17. Whitelock JM, Melrose J, Iozzo RV. Diverse cell signaling events modulated by perlecan. Biochemistry 2008; 47: 11174-83.
18. Katz BZ, Yamada KM. Integrins in morphogenesis and signaling. Biochimie 1997; 79: 467-76.
19. Talts JF, Andac Z, Göhring W, Brancaccio A, Timpl R. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J 1999; 18: 863-70.
20. Sgambato A, Brancaccio A. The dystroglycan complex: from biology to cancer. J Cell Physiol 2005; 205: 163-9.
21. Durbeej M, Talts JF, Henry MD, Yurchenco PD, Campbell KP, Ekblom P. Dystroglycan binding to laminin a1LG4 module influences epithelial morphogenesis of salivary gland and lung in vitro. Differentiation 2001; 69: 121-34.
22. Andac Z, Sasaki T, Mann K, Brancaccio A, Deutzmann R, Timpl R. Analysis of heparin, alpha-dystroglycan and sulfatide binding to the G domain of the laminin alpha1 chain by site-directed mutagenesis. J Mol Biol 1999; 287: 253-64.
23. Jing J, Lien CF, Sharma S, Rice J, Brennan PA, Górecki DC. Aberrent expression, processing and degradation of dystroglycan in squamous cell carcinoma. Eur J Cancer 2004; 40: 2143-51.
24. Sgambato A, Tarquini E, Resci F, et al. Aberrant expression of α-dystroglycan in cervical and vulvar cancer. Gynecol Oncol 2006; 103: 397-404.
25. Ida-Yonemochi H, Ahsan MS, Saku T. Differential expression profiles between α-dystroglycan and integrin β1 in ameloblastoma: two possible perlecan signaling pathways for cellular growth and differentiation. Histopathology, 2010; 56: in press.
26. Syafriadi M, Cheng J, Jen KY, Ida-Yonemochi H, Suzuki M, Saku T. Two-phase appearance of oral epithelial dysplasia resulting from focal proliferation of parabasal cells and apoptosis of prickle cells. J Oral Pathol Med 2005; 34: 140-9.
27. Saku T, Furthmayr H. Characterization of the major heparan sulfate proteoglycan secreted by bovine aortic endothelial cells in culture. Homology to the large molecular weight molecule of basement membranes. J Biol Chem 1989; 264: 3514-23.
28. Kocher O, Amaudruz M, Schindler AM, Gabbiani G. Desmosomes and gap junctions in precarcinomatous and carcinomatous conditions of squamous epithelia. An electron microscopic and morphometrical study. J Submicrosc Cytol 1981; 13: 267-81.
29. Kimura S, Cheng J, Toyoshima K, Oda K, Saku T. Basement membrane heparan sulfate proteoglycan (perlecan) synthesized by ACC3, adenoid cystic carcinoma cells of human salivary gland origin. J Biochem 1999; 125: 406-13.
30. Jiang X, Multhaupt H, Chan E, Schaefer L, Schaefer RM, Couchman JR. Essential contribution of tumor-derived perlecan to epidermal tumor growth and angiogenesis. J Histochem Cytochem 2004; 52: 1575-90.
31. Adatia R, Albini A, Carlone S, et al. Suppression of invasive behavior of melanoma cells by stable expression of antisense perlecan cDNA. Ann Oncol 1997; 8: 1257-61.
32. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 1998; 102: 1599-608.
33. Henry MD, Campbell KP. A role for dystroglycan in basement membrane assembly. Cell 1998; 95: 859-70.
34. Sgambato A, Di Salvatore MA, De Paola B, et al. Analysis of dystroglycan regulation and functions in mouse mammary epithelial cells and implications for mammary tumorigenesis. J Cell Physiol 2006; 207: 520-9.
35. Henry MD, Cohen MB, Campbell KP. Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol 2001; 32: 791-5.
36. Sgambato A, Migaldi M, Montanari M, et al. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 2003; 162: 849-60.
37. Sgambato A, Caredda E, Leocata P, et al. Expression of alpha-dystroglycan correlates with tumour grade and predicts survival in oral squamous cell carcinoma. Pathology 2010; 42: 248-54.
38. Yamada H, Saito F, Fukuta-Ohi H, et al. Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 2001; 10: 1563-9.
39. Shang ZJ, Ethunandan M, Górecki DC, Brennan PA. Aberrant expression of beta-dystroglycan may be due to processing by matrix metalloproteinases-2 and -9 in oral squamous cell carcinoma. Oral Oncol 2008; 44: 1139-46.
40. Siqueira AS, Gama-de-Souza LN, Arnaud MV, Pinheiro JJ, Jaeger RG. Laminin-derived peptide AG73 regulates migration, invasion, and protease activity of human oral squamous cell carcinoma cells through syndecan-1 and beta1 integrin. Tumour Biol 2010; 31: 46-58.
41. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev 2010; 29: 223-37.
42. Henry MD, Satz JS, Brakebusch C, et al. Distinct roles for dystroglycan, β1 integrin and perlecan in cell surface laminin organization. J Cell Sci 2001; 114: 1137-44.
43. Peng H, Shah W, Holland P, Carbonetto S. Integrins and dystroglycan regulate astrocyte wound healing: the integrin beta1 subunit is necessary for process extension and orienting the microtubular network. Dev Neurobiol 2008; 68: 559-74.